286 related articles for article (PubMed ID: 18178361)
1. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
Fritsche TR; Rhomberg PR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
[TBL] [Abstract][Full Text] [Related]
2. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital.
Sancak B; Ercis S; Menemenlioglu D; Colakoglu S; Hasçelik G
J Antimicrob Chemother; 2005 Sep; 56(3):519-23. PubMed ID: 16046461
[TBL] [Abstract][Full Text] [Related]
3. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.
Sader HS; Fritsche TR; Jones RN
Antimicrob Agents Chemother; 2006 Jul; 50(7):2330-6. PubMed ID: 16801409
[TBL] [Abstract][Full Text] [Related]
4. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
[TBL] [Abstract][Full Text] [Related]
5. Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci.
Franchi D; Climo MW; Wong AH; Edmond MB; Wenzel RP
Clin Infect Dis; 1999 Dec; 29(6):1566-8. PubMed ID: 10585815
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.
Hussain FM; Boyle-Vavra S; Shete PB; Daum RS
J Infect Dis; 2002 Sep; 186(5):661-7. PubMed ID: 12195353
[TBL] [Abstract][Full Text] [Related]
7. [Prospective study of Staphylococcus aureus with reduced susceptibility to glycopeptides].
Cantón R; Mir N; Martínez-Ferrer M; Sánchez del Saz B; Soler I; Baquero F
Rev Esp Quimioter; 1999 Mar; 12(1):48-53. PubMed ID: 10896469
[TBL] [Abstract][Full Text] [Related]
8. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.
Fridkin SK; Hageman J; McDougal LK; Mohammed J; Jarvis WR; Perl TM; Tenover FC;
Clin Infect Dis; 2003 Feb; 36(4):429-39. PubMed ID: 12567300
[TBL] [Abstract][Full Text] [Related]
9. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
Howden BP
Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
[TBL] [Abstract][Full Text] [Related]
10. [Detection methods for drug-resistant bacteria in routine examination--VISA].
Kinoshita S; Nakamachi Y
Rinsho Byori; 2000 Jan; Suppl 111():69-74. PubMed ID: 10804795
[TBL] [Abstract][Full Text] [Related]
11. Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Jan; 48(51-52):1165-7. PubMed ID: 11266244
[TBL] [Abstract][Full Text] [Related]
12. MRSA--the tip of the iceberg.
Appelbaum PC
Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of laboratory-generated vancomycin intermediate resistant Staphylococcus aureus strains.
Bhateja P; Purnapatre K; Dube S; Fatma T; Rattan A
Int J Antimicrob Agents; 2006 Mar; 27(3):201-11. PubMed ID: 16417988
[TBL] [Abstract][Full Text] [Related]
14. Staphylococcus aureus resistant to vancomycin--United States, 2002.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Jul; 51(26):565-7. PubMed ID: 12139181
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
Leuthner KD; Cheung CM; Rybak MJ
J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin intermediate and resistant Staphylococcus aureus. What the nephrologist needs to know.
McDonald LC; Hageman JC
Nephrol News Issues; 2004 Oct; 18(11):63-4, 66-7, 71-2 passim. PubMed ID: 15551615
[TBL] [Abstract][Full Text] [Related]
18. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Appelbaum PC
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():16-23. PubMed ID: 16445720
[TBL] [Abstract][Full Text] [Related]
19. [Searching for Staphylococcus aureus strains with reduced susceptibility to glycopeptides among clinical isolates obtained during the year of 2002].
Młynarczyk A; Młynarczyk G; Łuczak M
Med Dosw Mikrobiol; 2003; 55(3):209-17. PubMed ID: 14702662
[TBL] [Abstract][Full Text] [Related]
20. [Clinical relevance of hetero-VRSA in surgical infections].
Okii K; Takesue Y; Yokoyama T
Nihon Rinsho; 2001 Apr; 59(4):728-32. PubMed ID: 11304997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
